Format

Send to

Choose Destination
J Nucl Med. 2019 Jul;60(7):937-943. doi: 10.2967/jnumed.118.230607.

NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.

Author information

1
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California thomas.hope@ucsf.edu.
2
Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
3
Dana-Farber Cancer Institute, Boston, Massachusetts.
4
Lehigh Valley Health Network, Allentown, Pennsylvania.
5
Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa.
6
Iowa City VA Medical Center, Iowa City, Iowa.
7
Department of Nuclear Medicine, University of California, Los Angeles, Los Angeles, California.
8
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
9
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.
10
Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
11
Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
12
NV5/Dade Moeller, Richland, Washington; and.
13
Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida.

Abstract

With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing. Representatives from the North American Neuroendocrine Tumor Society and the Society of Nuclear Medicine and Molecular Imaging collaborated to develop a practical consensus guideline for the administration of 177Lu-DOTATATE. In this paper, we discuss patient screening, maintenance somatostatin analog therapy requirements, treatment location and room preparation, drug administration, and patient release as well as strategies for radiation safety, toxicity monitoring, management of potential complications, and follow-up. Controversies regarding the role of radiation dosimetry are discussed as well. This document is designed to provide practical guidance on how to safely treat patients with this therapy.

PMID:
31263080
DOI:
10.2967/jnumed.118.230607

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center